

# Cyril Fauriat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4717824/publications.pdf>

Version: 2024-02-01

48  
papers

4,323  
citations

201674

27  
h-index

243625

44  
g-index

50  
all docs

50  
docs citations

50  
times ranked

6705  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
2	Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor. Cancers, 2021, 13, 2673.	3.7	12
3	Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia. Frontiers in Immunology, 2021, 12, 756231.	4.8	11
4	Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia. Frontiers in Immunology, 2021, 12, 730970.	4.8	6
5	Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer. Frontiers in Immunology, 2019, 10, 1307.	4.8	56
6	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Frontiers in Immunology, 2018, 9, 977.	4.8	25
7	NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncoimmunology, 2017, 6, e1307491.	4.6	37
8	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. Cancer Research, 2017, 77, 6627-6640.	0.9	23
9	Feasibility and safety of allogeneic ex vivo activated-NK cell infusion after matched related hematopoietic stem cell transplantation: Preliminary results of a prospective phase I trial. Cytotherapy, 2017, 19, S16.	0.7	0
10	Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells. Frontiers in Immunology, 2017, 8, 64.	4.8	35
11	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2017, 8, 573.	4.8	47
12	NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia. Oncotarget, 2017, 8, 49548-49563.	1.8	34
13	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Frontiers in Immunology, 2016, 7, 94.	4.8	26
14	In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantation. European Journal of Immunology, 2016, 46, 1758-1769.	2.9	2
15	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. Immunology, 2015, 146, 173-183.	4.4	16
16	Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia. Frontiers in Immunology, 2015, 6, 564.	4.8	24
17	Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome. Biology of Blood and Marrow Transplantation, 2015, 21, 429-439.	2.0	55
18	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology, 2014, 5, 122.	4.8	75

#	ARTICLE	IF	CITATIONS
19	Activating Killer Cell Ig-Like Receptors in Health and Disease. <i>Frontiers in Immunology</i> , 2014, 5, 184.	4.8	64
20	B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. <i>Leukemia</i> , 2014, 28, 1163-1167.	7.2	54
21	AML drug resistance: c-Myc comes into play. <i>Blood</i> , 2014, 123, 3528-3530.	1.4	18
22	BTLA, a key regulator of $\text{V}\alpha 9\text{V}\beta 2$ T-cell proliferation. <i>Oncolimmunology</i> , 2013, 2, e25853.	4.6	7
23	The co-receptor BTLA negatively regulates human $\text{V}\alpha 9\text{V}\beta 2$ T-cell proliferation: a potential way of immune escape for lymphoma cells. <i>Blood</i> , 2013, 122, 922-931.	1.4	87
24	Immunotherapy of acute myeloid leukemia based on $\text{V}\alpha 3\text{V}\beta 1$ T cells. <i>Oncolimmunology</i> , 2012, 1, 1614-1616.	4.6	11
25	Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy. <i>Journal of Clinical Immunology</i> , 2012, 32, 632-646.	3.8	42
26	NK Cells Display Poor Anti Lymphoma and AML Function At Early Times Following Allogeneic HLA-Identical SCT for Leukemia and Lymphomas.. <i>Blood</i> , 2012, 120, 3045-3045.	1.4	0
27	ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3324-3329.	7.1	181
28	Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. <i>Journal of Experimental Medicine</i> , 2011, 208, 13-21.	8.5	414
29	Molecular Mechanisms of Natural Killer Cell Activation. <i>Journal of Innate Immunity</i> , 2011, 3, 216-226.	3.8	194
30	NK cells expressing inhibitory KIR for non-self ligands remain tolerant in HLA-matched sibling stem cell transplantation. <i>Blood</i> , 2010, 115, 2686-2694.	1.4	79
31	Regulation of human NK-cell cytokine and chemokine production by target cell recognition. <i>Blood</i> , 2010, 115, 2167-2176.	1.4	711
32	Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. <i>Blood</i> , 2010, 115, 1166-1174.	1.4	256
33	Natural killer cells in leukaemia. , 2010, , 533-541.		0
34	Functional Analysis of Human NK Cells by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2010, 612, 335-352.	0.9	122
35	Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. <i>Blood</i> , 2010, 116, 3853-3864.	1.4	654
36	Analysis of the KIR Repertoire in Human NK Cells by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2010, 612, 353-364.	0.9	24

#	ARTICLE	IF	CITATIONS
37	177-P: Maintained tolerance of NK cells expressing inhibitory KIR for non-self ligands in HLA-matched sibling stem cell transplantation. Human Immunology, 2009, 70, S100.	2.4	0
38	KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood, 2009, 114, 95-104.	1.4	93
39	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 1541-1552.	4.2	74
40	Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A <i>KIR</i> Haplotype. Journal of Immunology, 2008, 181, 6010-6019.	0.8	99
41	Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood, 2007, 109, 323-330.	1.4	321
42	Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia, 2006, 20, 732-733.	7.2	96
43	Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood, 2005, 106, 2186-2188.	1.4	60
44	NK cells: innate immunity against hematological malignancies?. Trends in Immunology, 2004, 25, 328-333.	6.8	65
45	Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. Lancet Oncology, The, 2004, 5, 47-55.	10.7	10
46	New approaches in the immunotherapy of haematological malignancies. European Journal of Haematology, 2003, 70, 333-345.	2.2	23
47	Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia. Leukemia and Lymphoma, 2003, 44, 1683-1689.	1.3	17
48	Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cellsâ€”evidence for a NF-Î²B-dependent survival mechanism. Cell Death and Differentiation, 2002, 9, 768-779.	11.2	34